S

    Structure Therapeutics Inc. American Depositary Shares (GPCR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $45.91
    -1.46 (-3.08%)

    Market Cap: $3.38B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    47%(7/15)
    Avg Surprise
    -12.79%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.23
    Range$-0.57 - $2.02
    10 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.15+34.2%
    60d ago$-0.19+19.7%
    30d ago$-0.19+19.7%
    7d ago$-0.23+0.0%
    Current$-0.23
    Revenue Consensus
    $50M
    Range$0 - $500M
    10 analysts
    Dec 31, 2026
    EPS Consensus$-0.70
    Range$-1.11 - $1.86
    12 analysts
    Revenue Consensus
    $-22649570
    Range$-61111110 - $439M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.70---
    Sep 26EST
    		-$-0.23---
    Jun 26
    		$-0.49$-0.39-25.64%Miss-36.1%
    Mar 26
    		$-0.35$-0.33-6.06%Miss-29.6%
    Dec 25
    		$-0.49$-0.35-40.00%Miss-133.3%
    Sep 25
    		$-0.37$-0.37+0.00%Beat-85.0%
    Jun 25
    		$-0.36$-0.28-28.57%Miss-100.0%
    Mar 25
    		$-0.27$-0.23-17.39%Miss-42.1%
    Dec 24
    		$-0.21$-0.28+25.00%Beat+60.5%
    Sep 24
    		$-0.20$-0.19-5.26%Miss+4.8%
    Jun 24
    		$-0.18$-0.23+21.74%Beat+10.0%
    Mar 24
    		$-0.19$-0.22+13.64%Beat+24.0%
    Dec 23
    		$-0.53$-0.21-153.14%Miss+53.4%
    Sep 23
    		$-0.21$-0.22+4.55%Beat-76.9%
    Jun 23
    		$-0.20$-0.27+25.93%Beat-57.4%
    Mar 23
    		$-0.25$-0.37+32.43%Beat-109.7%
    Dec 22
    		$-1.14$-0.82-39.02%Miss-1139900.0%
    Sep 22
    		$-0.12N/AN/ABeat-
    Jun 22
    		$-0.13N/AN/ABeat-
    Mar 22
    		$-0.12N/AN/ABeat-
    Dec 21
    		$-0.00N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-27.01EV/EBITDA-13.46x
    Price/FCF-14.85xFCF Yield-6.73%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-20.20%ROIC-12.52%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio20.75xQuick Ratio20.75x
    Trading Statistics
    Beta-1.51Avg Volume661.70K
    52-Week High$94.9052-Week Low$18.49

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$49.80
    SMA 20$51.34
    SMA 50$50.65
    SMA 200$54.15
    EMA 10$49.25
    EMA 20$50.12
    EMA 50$49.64
    EMA 200$47.62

    MACD

    Line: -0.62Signal: 0.18Hist: -0.80

    ADX

    ADX: 17.9+DI: 15.9-DI: 27.5

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down100.0
    PSAR$53.04

    Bollinger Bands

    Upper Band$56.54
    Lower Band$46.14
    %B Position2025%(Upper)
    Band Width-0.02

    RSI (14-Day)

    Neutral
    35.3

    Momentum Oscillators

    Stoch %K10.8
    Stoch %D16.6
    Williams %R-92.3
    ROC (10d)-14.6%
    Momentum-7.85
    CCI (20d)-166.9
    MFI (14d)43.5

    Volatility Measures

    ATR (14d)$2.36(5.1%)
    StdDev (20d)2.60
    Hist Vol42.6%(High)

    Volume Flow

    VWAP$46.13
    OBV27.2M
    AD Line-24.2M
    CMF (20d)0.021

    Volume Metrics

    Avg Vol (20d)678.5K
    Vol Ratio1.6x(High)
    VWMA (20d)$51.01

    Pivot Points

    R3$50.97
    R2$50.08
    R1$48.73
    Pivot Point$47.84
    S1$46.49
    S2$45.60
    S3$44.25

    Advanced Oscillators

    TSI-7.36
    Ultimate Osc43.2
    KST-6.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.78M$0$0$0$1.33M$0
    Cost of RevenueN/A$1.22MN/AN/A$853,991$686,976N/A$267,175$231,736$658,927$280,918$351,022
    Gross ProfitN/A$-1,218,622N/AN/A$-853,991$-686,976$890,663$-267,175$-231,736$-658,927$1.05M$-351,022
    Operating Expenses$118.63M$88.43M$-23,989,000$73.79M$70.45M$56.31M$47.06M$45.84M$33.32M$32.02M$30.99M$26.14M
    R&D$100.06M$66.71M$68.69M$58.99M$54.71M$42.87M$33.49M$32.60M$22.05M$20.68M$20.04M$17.52M
    SG&A$18.57M$22.87M$17.57M$14.80M$15.74M$13.44M$13.57M$13.24M$11.27M$11.34M$10.95M$8.63M
    Operating Income$-118,630,000$-89,645,505$23.99M$-73,787,000$-70,451,000$-56,311,000$-47,061,000$-45,836,000$-33,316,000$-32,015,000$-30,994,000$-26,145,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$6.01M$9.58M$2.83M
    Income Before Tax$-105,925,000$-76,003,951$33.17M$-65,604,000$-61,522,000$-46,735,000$-36,343,000$-33,885,000$-25,981,000$-26,007,000$-24,815,000$-23,457,000
    Income Tax Expense$234,000$190,566$170,000$108,000$139,000$98,000$136,000$92,000$53,000$29,000$-312,000$405,000
    Net Income$-106,159,000$-76,194,517$33.00M$-65,712,000$-61,661,000$-46,833,000$-36,479,000$-33,977,000$-26,034,000$-26,036,000$-24,503,000$-23,862,000
    EBITDA$-105,925,000$-74,785,329$33.59M$-65,313,000$-61,231,000$-46,461,000$-36,070,000$-33,620,000$-25,749,000$-25,785,000$-24,743,000$-23,378,000
    EBITN/A$-76,003,951$33.17M$-65,604,000$-61,522,000$-46,735,000$-36,343,000$-33,885,000$-25,981,000$-26,007,000$-24,815,000$-23,457,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GPCR

    News

    Structure Therapeutics' oral GLP-1 drug shows 16.2% weight loss, advancing to Phase 3 with strong cash backing.

    Structure Therapeutics' oral GLP-1 drug, aleniglipron, achieved up to 16.2% weight loss in Phase 2b trials for obesity, prompting its progression to Phase 3. The drug demonstrated a favorable safety profile, and the company has $1.34 billion in cash to fund its development through pivotal data expected by Q4 2028. Despite competitive risks and potential Phase 3 failure, the drug's efficacy and cost-effectiveness suggest blockbuster potential.

    Pluang•8/22/26•
    Bullish

    Structure Therapeutics can't force chief financial officer’s harassment claim into arbitration

    The Ninth Circuit Court of Appeals affirmed a ruling that prevents Structure Therapeutics from forcing a former CFO's sexual harassment claim into arbitration. The decision hinges on the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act of 2021 (EFAA), which allows employees to cancel predispute arbitration agreements for such claims. The court ruled that the CFO's initial arbitration filing for other discrimination claims did not count as an EFAA election, as she discovered evidence of sexual harassment only during the discovery process.

    Human Resources Director•8/20/26•
    Somewhat-Bearish

    Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR

    Handelsbanken Fonder AB recently acquired 19,400 shares of Structure Therapeutics Inc. Sponsored ADR (GPCR) for approximately $1.04 million in the second quarter. Institutional investors now collectively own 91.78% of the company's stock. Despite missing earnings estimates in its last report, analysts have a "Moderate Buy" consensus rating for GPCR with an average price target of $110.91.

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan

    Structure Therapeutics' Chief Scientific Officer, Xichen Lin, reported insider activity on August 18, 2026, which included exercising options for 11,817 Ordinary Shares and converting them into 3,939 American Depositary Shares (ADSs). All 3,939 ADSs were subsequently sold in three tranches at weighted average prices between $53.133 and $55.05 per ADS, under a Rule 10b5-1 trading plan. Following these transactions, Lin retains an option for 142,898 Ordinary Shares.

    Stock Titan•8/20/26•
    Neutral

    J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $100

    J.P. Morgan has reiterated its Buy rating for Structure Therapeutics (GPCR.US) and set a target price of $100. This indicates a positive outlook from the investment bank regarding the company's future performance.

    Moomoo•8/17/26•
    Bullish

    Frequently Asked Questions About GPCR

    Does GPCR pay dividends?
    Structure Therapeutics Inc. American Depositary Shares (GPCR) does not currently pay a regular dividend.
    What is GPCR's market cap?
    Structure Therapeutics Inc. American Depositary Shares (GPCR) has a market capitalization of $3.38B with a current stock price of $45.91.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In